EU Trade Department Faces Scrutiny Over Contacts With Tobacco Industry

Aug.24
EU Trade Department Faces Scrutiny Over Contacts With Tobacco Industry
European Ombudswoman Teresa Anjinho has opened an inquiry into how the European Commission’s Directorate-General for Trade handles interactions with the tobacco industry. The case follows a complaint from a civil society organisation that alleges regular, unnecessary and non-transparent contacts between DG TRADE and tobacco industry representatives, raising questions over compliance with the EU’s obligations under the WHO Framework Convention on Tobacco Control. The inquiry remains ongoing, and the Ombudswoman has not reached any finding of maladministration.

Key Points

  • The European Ombudswoman formally opened Case 1036/2026/AML on August 18, 2026.
  • The inquiry examines how DG TRADE handles interactions with the tobacco industry, including their necessity and transparency.
  • The complainant alleges the contacts may conflict with EU obligations under the WHO Framework Convention on Tobacco Control, but no finding has yet been made.
  • The Ombudswoman has requested access to Commission documents concerning interactions with the tobacco industry.
  • In 2023, the Ombudsman found maladministration in the Commission’s handling of transparency and necessity assessments for meetings with tobacco lobbyists.

2Firsts

August 24, 2026

European Ombudswoman Teresa Anjinho has opened an inquiry into how the European Commission’s Directorate-General for Trade (DG TRADE) handles interactions with the tobacco industry, IEU Monitoring reported on August 20, 2026.

The European Ombudsman’s Office said the case, numbered 1036/2026/AML, was formally opened on August 18. As a first step, the Ombudswoman has asked to inspect Commission documents concerning its interactions with the tobacco industry.

The inquiry remains ongoing and no finding has been made that DG TRADE engaged in maladministration or breached applicable obligations.

Complaint Questions Necessity and Transparency of Tobacco Contacts

The inquiry follows a complaint from a civil society organisation specialising in efforts to reduce tobacco consumption and exposure to tobacco smoke.

Based on information obtained through public access-to-documents requests, the organisation alleges that DG TRADE engaged in regular, unnecessary and non-transparent interactions with the tobacco industry.

The complainant also argues that such interactions risk undermining tobacco-control and public-health policies in countries outside the EU, particularly low- and middle-income countries.

Those claims are allegations made by the complainant and have not been established by the Ombudswoman.

The organisation further contends that the interactions may conflict with the EU’s obligations under the World Health Organization Framework Convention on Tobacco Control (FCTC).

Ombudswoman Requests Commission Documents

The Ombudswoman has begun the inquiry by seeking access to Commission documents concerning contacts with the tobacco industry.

The complaint was submitted on April 30, 2026, before progressing through analysis and inquiry procedures. The case was formally opened on August 18.

At this stage, the inquiry is examining how DG TRADE manages those interactions and whether its practices comply with applicable transparency and administrative requirements.

The opening of the case does not itself constitute a finding against DG TRADE.

Commission Previously Found at Fault Over Tobacco Lobbying Transparency

The latest inquiry follows an earlier Ombudsman investigation into the European Commission’s handling of tobacco industry contacts.

In 2023, the Ombudsman found maladministration in the Commission’s failure to ensure transparency consistently across its departments in relation to meetings with tobacco lobbyists.

The Ombudsman also found that the Commission had failed to ensure that all departments systematically assessed whether specific meetings with tobacco industry representatives were necessary.

The Commission subsequently carried out a risk assessment of departments’ exposure to tobacco industry lobbying and adopted measures intended to improve how such contacts are handled.

The new inquiry focuses specifically on DG TRADE and how the department currently manages interactions with tobacco industry representatives.

FCTC Obligations Form Part of the Inquiry

The case also raises questions about the EU’s obligations under the WHO Framework Convention on Tobacco Control.

Under the FCTC framework, parties are required to protect tobacco-control public-health policies from the commercial and other vested interests of the tobacco industry. Related implementation principles call for unnecessary interactions with the tobacco industry to be limited and for necessary contacts to be conducted transparently.

The complainant has relied on those obligations in challenging DG TRADE’s practices.

The Ombudswoman will now examine the relevant documentation and determine whether there was maladministration and whether further action by the European Commission is required.

Follow 2Firsts for the latest developments in global tobacco and nicotine regulation, policy and compliance.

Cover Image Source: IEU Monitoring


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello said legal tobacco sales in the country have fallen by more than half over the past decade, with sales declining more than 20% in 2025 compared with the previous year. She warned that the decline may not fully reflect lower smoking rates, as increased availability of illicit cigarettes could also be contributing. The government said it would continue strengthening tobacco and vape retail enforcement while monitoring the impact of illicit tobacco on public health and tax revenue.
Aug.26
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06